Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025)

Shots: PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics. The report tracks the rise and fall of leading biopharma companies over two decades driven by…

ByPrince Giri2 days ago

Merck to Acquire Cidara Therapeutics for ~$9.2B to Bolster Antiviral Pipeline

Shots: Merck has signed a definitive agreement to acquire Cidara Therapeutics through a subsidiary, adding the company’s lead late-stage antiviral candidate CD388 to its pipeline Merck will acquire Cidara at $221.50 per share in cash, valuing the deal at approximately $9.2B. The transaction is expected to close in Q1’26 Cidara’s CD388 (currently in P-III) is…

ByRidhi RastogiNovember 17, 2025

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Shots: Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65 Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure After…

BySaurabh ChaubeyNovember 8, 2025

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025)

Merck to Acquire Cidara Therapeutics for ~$9.2B to Bolster Antiviral Pipeline

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Contact US

FOLLOW US